- General
- January 4, 2021
- 3 minutes read
Moderna Ups Vaccine Production Target
The American biotech company Moderna has increased the production target for its Covid-19 vaccine for this year, now seeking to…
The American biotech company Moderna has increased the production target for its Covid-19 vaccine for this year, now seeking to produce 600 million doses this year compared to a previously stated 500 million doses.
Out of the targeted 600 million, 100 million doses are targeted to be available in the US by the end of the first quarter of this year and 200 million by the end of the second quarter. Already, 18 million doses have been supplied to the US government.
Moderna received Emergency Use Authorization from the US last year December and began supplying to the government. Shortly after, it received approval from neighboring Canada and has also began supplying vaccines there.
Moderna has partnered with a clique of pharmaceutical firms for the mass production and distribution of its Covid vaccines. It’s secured big supply deals with a handful of countries, including 200 million doses ordered by the US, 40 million by Canada, and 7 million by the UK.
Moderna is a forerunner in the production and distribution of Covid-19 vaccines, alongside Pfizer-BioNTech and AstraZeneca-Oxford. Its vaccine was the second to be approved for use in the US after that jointly developed by Pfizer and BioNTech.
